Cancer Letters

Cancer Letters

Volume 191, Issue 2, 10 March 2003, Pages 179-185
Cancer Letters

Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability

https://doi.org/10.1016/S0304-3835(02)00633-XGet rights and content

Abstract

Methylenetetrahydrofolate reductase (MTHFR) is an essential enzyme in the folate metabolism, which affects DNA synthesis and methylation. Low enzyme activity may reduce the capacity of DNA methylation, and possibly reduce uracil misincorporation into DNA, which can result in double strand breaks. Both processes may be critical for the oncogenic transformation of human cells. Two common amino acid-changing and enzyme activity-reducing nucleotide polymorphisms (677C→T/Ala222Val and 1298A→C/Glu428Ala) have been described in MTHFR. We performed estimations of the relative risk associated with these two polymorphisms in samples from 287 colorectal cancer patients, compared to 346 healthy controls. Relative risk were further determined for subpopulations of cancer patients having sporadic (n=227) or suspected/verified hereditary disease (n=60) and tumours exhibiting high-level microsatellite instability (n=41) or not (n=246). No significant differences for the relative risk of colorectal cancer were observed for the MTHFR genotypes either alone or in combination in the analysed cohorts, although the frequency of the 1298AA+AC genotypes was increased among the 60 cases with hereditary disease. Whereas our results do not support an association of high enzyme activity and increased risk of colorectal cancer in general, we can not exclude an association of patients with hereditary disease and the MTHFR 1298A→C variant.

Introduction

The human methylenetetrahydrofolate reductase (MTHFR) gene is located on chromosome 1p36.3 and encodes for a 656-amino-acid protein which acts as a homodimer [1]. MTHFR catalyses the formation of a methyl-donor, 5-methyltetrahydrofolate, acting in the remethylation of homocysteine to methionine [2]. MTHFR deficiency leads to an increased risk of clinical manifestations including developmental delay, premature vascular disease and neural-tube defects in newborn [3]. Reduced MTHFR enzyme activity increases the pool of methylenetetrahydrofolate which, in turn, reduces the pool of uracil. The misincorporation of uracil during DNA synthesis can result in DNA double strand breaks during excision repair processes [4]. Moreover, MTHFR deficiency might affect the level of DNA methylation due to reduced S-adenosylmethionine [5], [6]. It is widely accepted that both processes, DNA damage and DNA methylation, may be critical for the oncogenic transformation of human cells, providing a possible link between MTHFR and carcinogenesis.

Two common single nucleotide polymorphisms (SNPs) resulting in amino-acid changes (677C→T/Ala222Val and 1298A→C/Glu428Ala) have been described in MTHFR. The first variant reduces the enzyme activity and renders it more susceptible to heat inactivation [7]. With the second variant the MTHFR enzyme activity is reduced in homozygotes and, to a lesser extent, in heterozygotes [8]. Moreover, this variant might interact with the T allele at position 677 in reducing the plasma folate level [9]. The T allele at nucleotide 677 has been associated with a reduced risk of colorectal cancer [10], especially under adequate dietary folate intake and low alcohol consumption [11], [12]. More recently, an increased risk of CRC has been associated with the 677T/T genotype in older populations, especially with tumours showing microsatellite instability [13]. The C allele at nucleotide 1298 has shown to be associated with a decreased risk of adult acute lymphocytic leukaemia (ALL), but not with acute myeloid leukaemia (AML) [14]. In colorectal cancer a slightly reduced risk with the 1298 C allele, independent from the 677 polymorphism, has been reported [15].

In the present study we analysed a series of 287 patients with colorectal cancer for both amino-acid-changing variants. Analyses separated for subtypes of cases, as sporadic and hereditary cases, might enhance the detection of effects of low penetrance genes. Moreover, hypermethylation of the hMLH1 promoter is frequently found in hMLH1-deficient MSI-H tumours [16], thus, providing a possible link between those tumours and genes affecting methylation capacity. We estimated the relative risk associated with each of the different genotypes for groups of patients with sporadic disease, with suspected/verified hereditary disease and for patients with tumours exhibiting or not exhibiting high levels of microsatellite instability (MSI-H). In contrast to some of the previously reported results no significant differences for the relative risk were identified for any of the genotypes or alleles in any of the groups of patients investigated.

Section snippets

Patients

Peripheral blood and tumour samples from 227 patients with sporadic primary colorectal cancer and 60 patients fulfilling the Bethesda guidelines for the hereditary non-polyposis colorectal cancer (HNPCC) syndrome were collected at the time of surgery. All patients originated from Saxony, Germany. The Bethesda guidelines were developed to aid in the identification of patients with HNPCC [17], including (B1) patients of families with at least three members affected with histological verified

Results

Among the 287 patients diagnosed with colorectal cancer, the frequency of the MTHFR 677T allele (32.4%) was almost identical to the 34.0% found in 346 healthy controls. A similar correspondence was seen for the 1298C allele with 31.9% in tumour patients versus 34.0% in controls. The frequencies of the different genotypes for both variants did not differ significantly between the two populations, although the heterozygous 677C/T genotype was less frequent among tumour patients (41.8 versus 45.9%

Discussion

In the present study, we have analysed patients with sporadic or hereditary colorectal cancer for two common amino acid-changing polymorphisms in the MTHFR gene. We did not identify an association between the two groups of patients and the alleles, genotypes or the combined genotypes. Our results corroborate recent findings of a lack of association with colorectal adenomas and hyperplastic polyps [19], [20], [21], but disagree with those showing that the MTHFR 677T/T genotype is associated with

Acknowledgements

We thank Ms. M. Biesold for excellent technical assistance.

References (28)

  • K.J.A Lievers et al.

    A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk

    J. Mol. Med.

    (2001)
  • J Chen et al.

    A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer

    Cancer Res.

    (1996)
  • J Ma et al.

    Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer

    Cancer Res.

    (1997)
  • L Le Marchand et al.

    B-vitamin intake, metabolic genes, and colorectal cancer risk

    Cancer Causes Control

    (2002)
  • Cited by (42)

    • Methylenetetrahydrofolate Reductase (MTHFR) Gene C677T, A1298C and G1793A Polymorphisms: Association with Risk for Clear Cell Renal Cell Carcinoma and Tumour Behaviour in Men

      2012, Clinical Oncology
      Citation Excerpt :

      However, some other studies reported a decreased risk of childhood acute lymphoblastic leukaemia [31], colorectal cancer [32], non-Hodgkin’s lymphoma [33] and malignant lymphoma [34]. Additional studies showed no association between MTHFR and breast cancer [35], endometrial cancer [36], childhood acute leukaemia [37] and colorectal cancer [38]. These conflicting results are difficult to resolve.

    View all citing articles on Scopus
    View full text